文献速递眼底病与葡萄膜炎

糖尿病黄斑水肿中与视力相关的基线OCT生物标志物:系统综述与荟萃分析

Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis.
PubMed 文献 · Ophthalmology · 2025-08-11

该研究系统检索Ovid MEDLINE、EMBASE和CENTRAL数据库,纳入27项研究的28篇报告、评估75种生物标志物,采用GRADE分级评价证据确定性。结果显示,无生物标志物达到中等及以上确定性且与视力改善或视力变化相关;基线超反射视网膜灶、超反射脉络膜灶、视网膜内层结构紊乱、椭圆体带或外界膜断裂及视锥外段终止线断裂与2个或以上时间点视力较差相关,证据确定性为中等。

要点

  • 基线超反射视网膜灶与6个月视力降低6.5个ETDRS字母、12个月降低7.3个字母相关,证据确定性为中等。
  • 基线视网膜内层结构紊乱与6个月视力降低6.0个字母、12个月降低7.3个字母相关,证据确定性为中等。
  • 基线椭圆体带或外界膜断裂与6个月视力降低9.7个字母、12个月降低7.5个字母相关,证据确定性为中等。

核心结论

  • 无生物标志物达到中等及以上证据确定性且与视力改善或视力变化相关。
  • 基线超反射视网膜灶、超反射脉络膜灶、视网膜内层结构紊乱、椭圆体带或外界膜断裂及视锥外段终止线断裂与2个或以上时间点视力较差相关,证据确定性为中等。
  • 需要提高生物标志物分类的标准化程度并更好地控制混杂变量。

研究设计与样本

  • 本综述在国际前瞻性系统综述注册平台注册,注册号为CRD42023487798。
  • 检索Ovid MEDLINE、EMBASE和CENTRAL数据库。
  • 采用推荐分级的评估、制定与评价(GRADE)指南评价证据确定性。
  • 纳入27项研究的28篇报告,评估75种生物标志物。

主要发现

  • 基线超反射视网膜灶与6个月视力降低6.5个ETDRS字母(95%CI,-10.4至-2.6)、12个月降低7.3个字母(95%CI,-11.6至-3.0)相关,证据确定性为中等。
  • 基线超反射脉络膜灶与6个月视力降低7.3个ETDRS字母(95%CI,-13.3至-1.3)、12个月降低7.5个字母(95%CI,-11.9至-3.0)相关,证据确定性为中等。
  • 基线视网膜内层结构紊乱与6个月视力降低6.0个ETDRS字母(95%CI,-11.7至-0.3)、12个月降低7.3个字母(95%CI,-12.8至-1.7)相关,证据确定性为中等。
  • 基线椭圆体带或外界膜断裂与6个月视力降低9.7个ETDRS字母(95%CI,-15.4至-3.9)、12个月降低7.5个字母(95%CI,-11.9至-3.0)、12个月孤立椭圆体带断裂降低5.4个字母(95%CI,-9.2至-1.6)、24个月降低9.0个字母(95%CI,-14.3至-3.6)相关,证据确定性为中等。
  • 基线视锥外段终止线断裂与12个月视力降低8.5个ETDRS字母(95%CI,-13.5至-3.5)、24个月降低8.8个字母(95%CI,-14.0至-3.6)相关,证据确定性为中等。

关键数值与推荐

  • 基线超反射视网膜灶:6个月视力变化-6.5个ETDRS字母(95%CI,-10.4至-2.6),12个月-7.3个字母(95%CI,-11.6至-3.0),证据确定性为中等。
  • 基线超反射脉络膜灶:6个月视力变化-7.3个ETDRS字母(95%CI,-13.3至-1.3),12个月-7.5个字母(95%CI,-11.9至-3.0),证据确定性为中等。
  • 基线视网膜内层结构紊乱:6个月视力变化-6.0个ETDRS字母(95%CI,-11.7至-0.3),12个月-7.3个字母(95%CI,-12.8至-1.7),证据确定性为中等。
  • 基线椭圆体带或外界膜断裂:6个月视力变化-9.7个ETDRS字母(95%CI,-15.4至-3.9),12个月-7.5个字母(95%CI,-11.9至-3.0),12个月孤立椭圆体带断裂-5.4个字母(95%CI,-9.2至-1.6),24个月-9.0个字母(95%CI,-14.3至-3.6),证据确定性为中等。
  • 基线视锥外段终止线断裂:12个月视力变化-8.5个ETDRS字母(95%CI,-13.5至-3.5),24个月-8.8个字母(95%CI,-14.0至-3.6),证据确定性为中等。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要提高生物标志物分类的标准化程度并更好地控制混杂变量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TOPIC: To determine effect estimates and certainty of evidence for the associations between baseline OCT biomarkers and (1) patient visual acuity (VA) and (2) changes in VA from baseline to 6, 12, and 24 months after initiation of anti-vascular endothelial growth factor, steroid, or laser treatment for diabetic macular edema. CLINICAL RELEVANCE: Understanding the prognostic value conferred by biomarkers can help predict disease activity and inform treatment decisions. METHODS: This review was registered in the International Prospective Register of Systematic Reviews (identifier, CRD42023487798). Ovid MEDLINE, EMBASE, and CENTRAL databases were searched. Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) guidelines informed certainty of evidence. RESULTS: Twenty-eight reports from 27 studies evaluating 75 biomarkers were included. No biomarker with at least a moderate certainty was associated with improved VA or change in VA. Results are reported in Early Treatment Diabetic Retinopathy Study letters. Five biomarkers were associated with reduced VA at 2 or more time points with moderate certainty: (1) hyperreflective retinal foci (HRF; 6 months, -6.5 [95% confidence interval (CI), -10.4 to -2.6]; 12 months, -7.3 [95% CI, -11.6 to -3.0], (2) hyperreflective choroidal foci (HCF; 6 months, -7.3 [95% CI, -13.3 to -1.3]; 12 months, -7.5 [95% CI, -11.9 to -3.0], (3) disorganization of retinal inner layers (DRIL; 6 months, -6.0 [95% CI, -11.7 to -0.3]; 12 months, -7.3 [95% CI, -12.8 to -1.7], (4) disrupted ellipsoid zone (EZ) or external limiting membrane (ELM; 6 months, -9.7 [95% CI, -15.4 to -3.9]; 12 months, -7.5 [95% CI, -11.9 to -3.0]; 12 months isolated EZ disruption, -5.4; [95% CI, -9.2 to -1.6] ; 24 months, -9.0 [95% CI, -14.3 to -3.6], and (5) disrupted cone outer segment termination (COST) line (12 months, -8.5 [95% CI, -13.5 to -3.5]; 24 months, -8.8 [95% CI, -14.0 to -3.6]. DISCUSSION: Baseline HRF, HCF, DRIL, disrupted EZ or ELM, and disrupted COST lines were associated with worse VA at 2 or more time points with moderate certainty of evidence. Greater standardization in biomarker classification and better control of confounding variables are needed. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Nanji K, Grad J, Hatamnejad A, et al. Baseline OCT Biomarkers Associated with Visual Acuity in Diabetic Macular Edema: A Systematic Review and Meta-analysis. Ophthalmology. 2025. PMID: 40803536. doi:10.1016/j.ophtha.2025.07.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。